N-Acetylcysteine Shifts Brain Connectivity and Glucose Metabolism in Multiple Sclerosis
A small randomized trial found that the antioxidant N-acetylcysteine altered brain connectivity and glucose metabolism in people with MS, alongside self-reported cognitive gains.
Summary
Multiple sclerosis (MS) damages the brain through both inflammation and oxidative stress, yet most approved drugs target only inflammation. A small randomized trial from Thomas Jefferson University tested N-acetylcysteine (NAC), an antioxidant that raises brain glutathione, in 36 people with mild to moderate MS. Half received weekly intravenous NAC plus oral NAC twice daily on top of standard care, and half received standard care alone. Functional MRI showed altered connectivity in the inferior frontal region, cerebellum, and parts of the temporal and parietal lobes in the NAC group. PET scans showed matching increases in glucose metabolism in several of those areas. Participants' self-reported improvements in cognition and attention tracked with these brain changes. The results are early and come from a small trial, but they suggest that targeting oxidative stress may complement existing MS treatments and protect brain function.
Detailed Summary
Multiple sclerosis affects about 2.8 million people worldwide, and 40 to 70 percent develop cognitive impairment. That impairment stems from both inflammation and oxidative stress, a known driver of neurodegeneration. Most approved MS therapies target inflammation, while almost none address oxidative stress. That gap is where this small trial, presented at the American Society of Functional Neuroradiology meeting and published in IBRO Neuroscience Reports, aimed to make progress.
Researchers at Thomas Jefferson University randomized 36 people with mild to moderate MS to N-acetylcysteine (NAC) plus standard care or to standard care alone, with 18 in each group. NAC is an antioxidant that raises glutathione, one of the brain's main defenses against oxidative damage. Because oral NAC absorbs variably, the treatment group received 50 mg/kg intravenously once a week plus 500 mg orally twice daily.
BOLD functional MRI showed significant connectivity changes in the inferior frontal region, cerebellum, and parts of the temporal and parietal lobes in the NAC group compared with controls. FDG-PET showed corresponding increases in cerebral glucose metabolism, including in the inferior frontal and inferior temporal gyri. Self-reported gains in cognition and attention correlated with these changes. The team says this is the first study to characterize connectivity and metabolism together in MS under NAC.
The work fits a wider pattern. The same group has reported NAC-related changes in dopamine function and connectivity in Parkinson's disease, and other research has suggested effects on resting-state connectivity and cognition after chronic mild traumatic brain injury. For readers focused on brain aging, it supports the idea that oxidative stress and glutathione status are modifiable targets.
The caveats are substantial. The trial is small, and cognitive outcomes were self-reported rather than objectively tested. The intravenous-plus-oral regimen is not the same as taking an over-the-counter supplement, and it is unclear whether imaging shifts translate into lasting clinical benefit. Larger, longer, blinded trials with objective cognitive testing are needed before NAC can be recommended for MS.
Key Findings
- Randomized trial of 36 people with mild to moderate MS tested NAC plus standard care versus standard care alone.
- fMRI showed altered connectivity in frontal, cerebellar, temporal, and parietal regions in the NAC group versus controls.
- FDG-PET showed matching increases in cerebral glucose metabolism, including the inferior frontal and inferior temporal gyri.
- Self-reported cognition and attention improvements correlated with the imaging changes.
- Regimen combined 50 mg/kg weekly intravenous NAC with 500 mg oral NAC twice daily to offset variable oral absorption.
Methodology
This is a news report on a conference presentation of a small randomized trial, also published in IBRO Neuroscience Reports. MedPage Today is a reputable medical news outlet quoting the investigators directly. The evidence is early-phase, based on imaging and self-reported outcomes in 36 participants.
Study Limitations
The sample was small, cognitive benefits were self-reported, and the article text is truncated before the full dosing duration and control details. Imaging changes do not prove lasting clinical benefit, and the article does not say whether participants or assessors were blinded. Check the IBRO Neuroscience Reports paper for outcome measures, safety data, and statistical details.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: